Type 2 diabetes mellitus therapeutic - Undisclosed company
Latest Information Update: 08 Oct 2013
At a glance
- Originator Unknown
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 30 Sep 2013 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)